1. Home
  2. QNTM vs CURB Comparison

QNTM vs CURB Comparison

Compare QNTM & CURB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QNTM
  • CURB
  • Stock Information
  • Founded
  • QNTM 1998
  • CURB 2024
  • Country
  • QNTM Canada
  • CURB United States
  • Employees
  • QNTM N/A
  • CURB N/A
  • Industry
  • QNTM
  • CURB
  • Sector
  • QNTM
  • CURB
  • Exchange
  • QNTM NYSE
  • CURB NYSE
  • Market Cap
  • QNTM 69.3M
  • CURB 2.4B
  • IPO Year
  • QNTM N/A
  • CURB N/A
  • Fundamental
  • Price
  • QNTM $18.56
  • CURB $22.83
  • Analyst Decision
  • QNTM
  • CURB Buy
  • Analyst Count
  • QNTM 0
  • CURB 7
  • Target Price
  • QNTM N/A
  • CURB $26.29
  • AVG Volume (30 Days)
  • QNTM 408.5K
  • CURB 546.7K
  • Earning Date
  • QNTM 08-13-2025
  • CURB 08-07-2025
  • Dividend Yield
  • QNTM N/A
  • CURB 2.83%
  • EPS Growth
  • QNTM N/A
  • CURB N/A
  • EPS
  • QNTM N/A
  • CURB 0.11
  • Revenue
  • QNTM N/A
  • CURB $131,537,000.00
  • Revenue This Year
  • QNTM N/A
  • CURB $34.07
  • Revenue Next Year
  • QNTM N/A
  • CURB $13.12
  • P/E Ratio
  • QNTM N/A
  • CURB $206.68
  • Revenue Growth
  • QNTM N/A
  • CURB 31.90
  • 52 Week Low
  • QNTM $2.70
  • CURB $18.80
  • 52 Week High
  • QNTM $38.25
  • CURB $25.69
  • Technical
  • Relative Strength Index (RSI)
  • QNTM 50.64
  • CURB N/A
  • Support Level
  • QNTM $15.88
  • CURB N/A
  • Resistance Level
  • QNTM $24.32
  • CURB N/A
  • Average True Range (ATR)
  • QNTM 3.58
  • CURB 0.00
  • MACD
  • QNTM -1.07
  • CURB 0.00
  • Stochastic Oscillator
  • QNTM 13.59
  • CURB 0.00

About QNTM QUANTUM BIOPHARMA LTD

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

About CURB CURBLINE PPTYS CORP

Curbline Properties Corp is engaged in the business of owning, managing, leasing and acquiring a portfolio of convenience shopping centers. The primary source of the Company's income is generated from the rental of the Company's convenience shopping centers to tenants. Convenience shopping centers are generally positioned on the curbline of well-trafficked intersections and major vehicular corridors, offering excellent access and visibility, dedicated parking and often include drive-thru units, with approximately half of Curbline properties having at least one drive-thru unit.

Share on Social Networks: